StockData

Smith & Nephew vs Steris

SNN and STE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SNN and STE compare

Steris grew revenue faster over the last twelve months (8.1% versus 6.1% for Smith & Nephew).

Steris pays a dividend yielding 0.76%; Smith & Nephew does not pay one.

Steris scores higher on the StockData Score (21 against 6 for Smith & Nephew), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSNNSTE
Size and price
Market cap–$25.0B
Share price$31.04$256.27
Change, 1 year−6.9%−2.9%
Change, 5 years−10.4%9.7%
Beta (5Y)0.620.75
Employees18K17K
StockData Score
Total score621 (better)
Valuation score03 (better)
Growth score13 (better)
Performance score15 (better)
Health score46 (better)
Dividend score04 (better)
Valuation
P/E–30.4×
P/S–4.1×
P/B–3.4×
EV/EBITDA–15.8×
P/FCF–26.7×
PEG–0.32
FCF yield–3.8%
Fair value–$263.20
Margin of safety–2.6%
Growth
Revenue growth (TTM)6.1%8.1% (better)
Revenue growth, 5Y average6.2%13.8% (better)
Net income growth (TTM)–20.1%
EPS growth (TTM)52.3% (better)21.3%
EPS growth, 5Y average6.9%11.4% (better)
Profitability
Gross margin68.0% (better)44.6%
Operating margin12.9%19.0% (better)
Net margin–13.4%
FCF margin–15.2%
Return on equity–11.6%
Return on invested capital13.0% (better)10.0%
Financial health
Debt / equity0.10 (better)0.26
Net debt / EBITDA−0.310.82 (better)
Interest coverage5.7×20.5× (better)
Current ratio2.14 (better)2.05
Altman Z-score–5.87
Piotroski F-score–9
Dividends and buybacks
Dividend yield–0.76%
Payout ratio–30.5%
Years of dividend growth–9
Dividend growth, 5Y average–9.4%
Buyback yield–1.4%
Shareholder yield–2.1%
Ownership
Held by institutions4.2%97.4%
Held by insiders25.1%0.34%
Insider net buying, 12 months–−$3.2M
Short interest, % of float–2.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.